Digestive Diseases and Sciences

, Volume 51, Issue 5, pp 968–975

Thiopurine Methyltransferase Deficiency and Azathioprine Intolerance in Autoimmune Hepatitis

Article

Abstract

Thiopurine methyltransferase deficiency has been associated with intolerance to azathioprine. Our goals were to assess the frequency of enzyme deficiency in autoimmune hepatitis and correlate deficiency states with azathioprine intolerance. Eighty-six patients receiving azathioprine (50–150 mg daily) were evaluated for enzyme activity and azathioprine-related complications. Their findings were compared to 89 similarly treated but untested patients. Thirteen patients (15%) had low thiopurine methyltransferase levels (11.4± 0.9 U/ml RBC; range, 3.5–14.9 U/ml RBC). Azathioprine intolerance occurred as commonly in patients with normal or above normal enzyme levels as in patients with below normal levels (12% versus 15%, p = 0.7). Patients treated without enzyme testing had the same frequency of complications (9% versus 13%, p = 0.5) as tested patients. We conclude that routine screening of blood thiopurine methyltransferase levels has a low yield for identifying individual patients at risk for azathioprine toxicity during conventional low dose therapy for autoimmune hepatitis.

Key Words

thiopurine methyltransferase azathioprine autoimmune hepatitis treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Czaja AJ, Freese DK: Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497, 2002PubMedCrossRefGoogle Scholar
  2. 2.
    Czaja AJ: Treatment of autoimmune hepatitis. Semin Liver Dis 22:365–377, 2002PubMedCrossRefGoogle Scholar
  3. 3.
    Bacon BR, Treuhaft WH, Goodman AM: Azathioprine-induced pancytopenia. Occurrence in two patients with connective tissue diseases. Arch Intern Med 141:223–226, 1981PubMedCrossRefGoogle Scholar
  4. 4.
    Hohlfeld R, Michels M, Heininger K, Besinger V, Toyka KV: Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 38:258–261, 1988PubMedCrossRefGoogle Scholar
  5. 5.
    Jeurissen MEC, Boerbooms AMTH, Van De Putte LBA: Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 47:503–505, 1988PubMedCrossRefGoogle Scholar
  6. 6.
    Maddocks JL, Lennard L, Amess J, Amor R, Meyrick Thomas R: Azathioprine and severe bone marrow depression. Lancet i:156, 1986CrossRefGoogle Scholar
  7. 7.
    Ben Ari Z, Mehta A, Lennard L, Burroughs AK: Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 23:351–354, 1995PubMedGoogle Scholar
  8. 8.
    Czaja AJ, Wolf AM, Baggenstoss AH: Clinical assessment of cirrhosis in severe chronic active liver disease (CALD): Specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc 55:360–364, 1980PubMedGoogle Scholar
  9. 9.
    Czaja AJ: Treatment strategies in autoimmune hepatitis. Clin Liver Dis 6:799-824, 2002PubMedGoogle Scholar
  10. 10.
    Johnson PJ, McFarlane IG, Williams R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333:958–963, 1995PubMedCrossRefGoogle Scholar
  11. 11.
    Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG: Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 37:441–447, 2002PubMedCrossRefGoogle Scholar
  12. 12.
    Dubinsky MC, Yang H, Hassard PV, et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122:904–915, 2002PubMedCrossRefGoogle Scholar
  13. 13.
    Cuffari C, Dassopoulis T, Turnbough L, Thompson RE, Bayless TM: Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2:410–417, 2004PubMedCrossRefGoogle Scholar
  14. 14.
    Black AJ, McLeod HL, Capell HA, et al.: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129:716–718, 1998PubMedGoogle Scholar
  15. 15.
    Lennard L, Welch JC, Lilleyman JS: Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 44:455–461, 1997PubMedCrossRefGoogle Scholar
  16. 16.
    McLeod HL, Krynetski EY, Relling MV, Evans WE: Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567–572, 2000PubMedCrossRefGoogle Scholar
  17. 17.
    Lichtenstein GR: Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology 127:1558–1564, 2004PubMedCrossRefGoogle Scholar
  18. 18.
    Regueiro M, Mardini H: Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn’s disease. J Clin Gastroenterol 35:240–244, 2002PubMedCrossRefGoogle Scholar
  19. 19.
    Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817–2823, 1999PubMedGoogle Scholar
  20. 20.
    Heneghan MA, McFarlane IG: Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35:7–13, 2002PubMedCrossRefGoogle Scholar
  21. 21.
    Bertino JR: Chemical action and pharmacology of methotrexate, azathioprine and cyclophosphamide in man. Arthritis Rheum 16:79–83, 1973PubMedGoogle Scholar
  22. 22.
    Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 43:329–39, 1992PubMedCrossRefGoogle Scholar
  23. 23.
    Chan GLC, Erdmann GR, Gruber SA, Matas AJ, Canafax DM: Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 30:358–363, 1990PubMedGoogle Scholar
  24. 24.
    Armstrong VW, Shipkova M, von Ahsen N, Oellerich M: Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 26:220–226, 2004PubMedCrossRefGoogle Scholar
  25. 25.
    Szumlanski C, Honchel R, Scott M, Weinshilboum RM: Human liver thiopurine methyltransferase pharmacogenetics: Biochemical properties, liver-erythrocyte correlation and presence of isoenzymes. Pharmacogenetics 2:148–159, 1992PubMedGoogle Scholar
  26. 26.
    Krynetski EY, Tai HL, Yates CR, et al.: Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 6:279–290, 1996PubMedGoogle Scholar
  27. 27.
    Otterness D, Szumlanski C, Lennard L, et al.: Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62:60–73, 1997PubMedCrossRefGoogle Scholar
  28. 28.
    Yates CR, Krynetski EY, Loennechen T, et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608–614, 1997PubMedGoogle Scholar
  29. 29.
    Alves S, Prata MJ, Ferreira F, Amorim A: Screening of thiopurine methyl s-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat 15:246–253, 2000PubMedCrossRefGoogle Scholar
  30. 30.
    McLeod HL, Lin JS, Scott EP, Pui C-H, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55:15–20, 1994PubMedCrossRefGoogle Scholar
  31. 31.
    Alvarez F, Berg PA, Bianchi FB, et al.: International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938, 1999PubMedCrossRefGoogle Scholar
  32. 32.
    Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clinica Chimica Acta 85:323–333, 1978CrossRefGoogle Scholar
  33. 33.
    Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Human Genet 32:651–662, 1980Google Scholar
  34. 34.
    Weinshilboum R: Methyltransferase pharmacogenetics. Pharmacol Ther 43:77–90, 1989PubMedCrossRefGoogle Scholar
  35. 35.
    Gisbert JP, Gonzalez-Guijarro L, Cara C, Pajares JM, Moreno-Otero R: Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med Clin (Barc) 121:481–484, 2003CrossRefGoogle Scholar
  36. 36.
    Czaja AJ, Carpenter HA: Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 39:1631–1638, 2004PubMedCrossRefGoogle Scholar
  37. 37.
    Czaja AJ, Carpenter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40:644–650, 2004CrossRefGoogle Scholar
  38. 38.
    Spire-Vayron de la Moureyre C, Debuysere J, Masain B, et al.: Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125:879–887, 1998CrossRefGoogle Scholar
  39. 39.
    McLeod HL, Pritchard SC, Githang’a J, et al.: Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence of allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 9:773–776, 1999PubMedGoogle Scholar
  40. 40.
    Weinshilboum R: Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 29:601–605, 2001PubMedGoogle Scholar
  41. 41.
    McLeod HL, Relling MV, Liu Q, Pui C-H, Evans WE: Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897–1902, 1995PubMedGoogle Scholar
  42. 42.
    Kaskas BA, Louis E, Hindorf U, et al.: Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut 52:140–142, 2003PubMedCrossRefGoogle Scholar
  43. 43.
    Sandborn WJ: Rational dosing of azathioprine and 6-mercaptopurine. Gut 48:591–592, 2001PubMedCrossRefGoogle Scholar
  44. 44.
    Cuffari C, Theoret Y, Latour S, Seidman G: 6-mercaptopurine metabolism in Crohn’s disease: Correlation with efficacy and toxicity. Gut 39:401–406, 1996PubMedGoogle Scholar
  45. 45.
    Dubinsky MC, Lamothe S, Yang HY, et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118:705–713, 2000PubMedCrossRefGoogle Scholar
  46. 46.
    Lowry PW, Franklin CL, Weaver AL, et al.: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 40:665–670, 2001CrossRefGoogle Scholar
  47. 47.
    Pettersson B, Almer S, Albertioni F, Soderhall S, Peterson C: Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate. Ther Drug Monit 24:351–358, 2002PubMedCrossRefGoogle Scholar
  48. 48.
    Reuter LO, Sonne J, Larsen NE, et al.: Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 38:972–979, 2003CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA
  2. 2.Department of Laboratory Medicine and PathologyMayo Clinic College of MedicineRochesterUSA
  3. 3.Mayo ClinicRochesterUSA

Personalised recommendations